News

Population-Based Study of Adolescent and Young Adult GIST Patients

Jason Sicklick, M.D Recent findings from a population-based retrospective cohort study at the at Moores Cancer Center at UC San Diego Health, led by senior author, Jason Sicklick, M.D., indicate that small [...]

By |2018-10-30T09:23:26-04:00January 25th, 2017|News, Research|

Study Highlights Role of ABL1 in GIST Treated with Imatinib

A recent study published in Oncotarget, discussed the potential role of the kinase, ABL1 as a potential impediment to anti-tumor processes in GIST treated with imatinib mesylate. The Life Raft Group’s Research Team member, [...]

By |2018-10-30T09:23:31-04:00January 19th, 2017|News, Research|

Columbia University Medical Center, NewYork-Presbyterian and The Life Raft Group, a Non-profit, Announce Innovative Partnership to Accelerate Cancer Research

New York, NY and Wayne, NJ - January 12, 2017 Columbia University Medical Center, NewYork-Presbyterian and the Life Raft Group (LRG), a patient advocacy organization specializing in GIST cancer, announced today that they have [...]

By |2021-03-04T11:01:59-05:00January 12th, 2017|News, Research|

NIH Pediatric and Wildtype GIST Clinic Report: Surgical Management

A recent report from the National Institutes of Health Pediatric and Wildtype GIST Clinic, published in the Journal of Clinical Oncology suggests that surgical resection for wildtype GIST should be restricted to the initial [...]

By |2018-10-30T09:25:10-04:00January 10th, 2017|News, Research|

Important Research Study Holds Hope for “Quadruple Wildtype” GIST Patients

A recent study published in the Journal of Translational Medicine, presents important research findings for the 10-15% of GIST patients who lack mutations in KIT, PDGFRA, SDHX or RAS pathway indicators, the primary oncogenic [...]

By |2018-10-30T09:25:15-04:00January 6th, 2017|News, Research|

Loxo Oncology Announces Plans for LOXO-101

In a recent press release, Loxo Oncology announced an update on the status of their TRK (tropomyosin receptor kinase) inhibitor drug, larotrectinib (LOXO-101). Larotrectinib targets the NTRK genes, which encode for the TRK kinases. [...]

By |2020-02-21T15:03:40-05:00December 22nd, 2016|Clinical Trials, News, Research|

7th Annual GIST Group Switzerland Prize Awarded to Professor Abbas Agaimy

Left to Right: Martin Wettstein, Dr. Michael Montemurro, Helga Meier Schnorf, Prof. Abbas Agaimy, Prof. Richard Herrmann GIST Group Switzerland, the support group for patients with gastrointestinal stromal tumor (GIST), has awarded [...]

By |2018-10-30T09:26:20-04:00December 19th, 2016|Global, News, Research|

Seminar for Chilean Patient Organizations Aligns Common Goals

On November 26, 2016, patient advocacy organizations in Chile came together at the School of Medicine at the University of San Sebastian in Santiago, Chile for a seminar entitled "Clinical Studies, Clinical Guidelines and [...]

By |2018-10-30T09:26:28-04:00December 12th, 2016|Advocacy, Events, Global, News|

Help MaKayla Realize Her Dream: Donate to double patient survival

MaKayla Evens help kick off our holiday campaign. MaKayla Evans was diagnosed with Wild Type GIST in 2011, when she was 14 years old. She wanted to speak knowledgeably with her doctors [...]

By |2020-01-31T11:01:40-05:00November 30th, 2016|Fundraising, Member Stories, News, Newsletter|
Go to Top